Anaplastic lymphoma tyrosine kinase oncogene in human cancer: gene aberrations, methods of detection and therapeutic potential

  • Rosalaura Sabetta Pathology Unit, Second University of Naples, Naples, Italy.
  • Monica Gargiulo Pathology Unit, Second University of Naples, Naples, Italy.
  • Marina Accardo Pathology Unit, Second University of Naples, Naples, Italy.
  • Federica Zito Marino Pathology Unit, Second University of Naples, Naples, Italy.
  • Renato Franco | renato.franco@unicampania.it Pathology Unit, Second University of Naples, Naples, Italy.

Abstract

Anaplastic lymphoma tyrosine kinase (ALK) gene could be an attractive oncotarget in human cancers, since it is involved in several genetic alterations resulting in an aberrant activity of the receptor. To date, ALK-rearrangement represents a molecular target for the treatment of ALK-rearranged Non Small Cell Lung Cancer patients, who are highly sensitive to crizotinib, a specific inhibitor. ALK-rearranged patients treated with crizotinib show relevant clinical implications, however several different resistance mechanisms have been identified. Here we review various critical issues related to ALK-targeting therapy, including ALK gene aberrations, methods of detection, mechanism of acquired resistance and second-generation ALK inhibitors.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2017-11-27
Info
Issue
Section
Review Articles
Keywords:
Anaplastic lymphoma kinase, Target therapy, Non small cell lung cancer
Statistics
  • Abstract views: 589

  • PDF: 316
How to Cite
Sabetta, R., Gargiulo, M., Accardo, M., Zito Marino, F., & Franco, R. (2017). Anaplastic lymphoma tyrosine kinase oncogene in human cancer: gene aberrations, methods of detection and therapeutic potential. Translational Medicine Reports, 2(1). https://doi.org/10.4081/tmr.6803